AZD2906 is primarily used in research and development within the pharmaceutical industry, particularly in the study of neurological and psychiatric disorders. It has been investigated for its potential role as a selective 5-HT1A receptor partial agonist, which could be beneficial in treating conditions like depression and schizophrenia. The compound is often utilized in preclinical studies to understand its efficacy and safety profile, helping researchers identify its therapeutic potential. Additionally, AZD2906 may be explored for its effects on specific biological targets in the central nervous system, contributing to the development of novel drug candidates aimed at improving mental health.